India shares higher at close of trade; Nifty 50 up 1.57%
Investing.com – India equities were higher at the close on Monday, as gains in the Banking, Metals and Public Sector Undertakings sectors propelled shares higher. At the close in NSE, the...
Buy
or
Cipla News & Analysis
-
-
Nifty Pharma stocks under pressure despite upbeat markets; Cipla emerges top loser
Strides Pharma and Natco Pharma led the gains to lend support to the sector.
-
India shares higher at close of trade; Nifty 50 up 0.87%
Investing.com – India equities were higher at the close on Friday, as gains in the Metals, Consumer Durables and Auto sectors propelled shares higher. At the close in NSE, the Nifty 50 rose...
-
13 Indian Drugmakers to Manufacture Anti-Covid Pill: Sun Pharma, Cipla & More
By Malvika Gurung Investing.com -- The antiviral pill for treating adult patients with the Covid-19 infection, Molnupiravir, received the emergency use authorization by the Central Drugs...
-
Stocks Under Focus on Dec 29: RIL, M&M, Natco Pharma & More
By Malvika Gurung Investing.com -- Reliance Industries: The telecom arm of the conglomerate is planning to raise up to Rs 8,000 crore through corporate bonds in the local market, and the...
-
Pharma firms to roll out anti-Covid pill as DCGI approves emergency use
Six other homegrown pharma companies announced rolling out their generic versions of the drug shortly
-
Pharma players to launch anti-Covid pill shortly after DCGI approval
Homegrown pharma majors Sun Pharma, Cipla, Hetero, Torrent announced plans to market their versions of antiviral drug Molnupiravir to treat high-risk adult patients with Covid across India...
-
Cipla to launch oral anti-viral covid drug Molnupiravir in India
The CDSCO has approved anti-Covid pill Molnupiravir along with 2 covid vaccines for restricted use in emergency situation
-
Nifty Pharma leads market revival; Index surges over 1%; Lupin, Cipla among top gainers
Laurus Labs, Torrent Pharma, Natco Pharma, and Glenmark Pharma outperformed. Pfizer was under pressure.
-
Top 5 Gainers Of Nifty 50, On December 23
Nifty has gained marginally by 0.69% today, on December 23. Nifty auto, Nifty pharma, and Nifty realty have performed significantly well today, by gaining by 0.74%, 0.71%, and 2.31%,...
-
Trade Spotlight | What should you do with Future Retail, Cipla, Bajaj Finance, and SBI now?
Here#39;s what Karan Pai of GEPL Capital, recommends investors should do with these stocks when the market resumes trading today.
-
Nifty50 Tanks Over 2% on Monday; Sensex Crashes Lowest in 4 Months
By Malvika Gurung Investing.com -- Witnessing a bloodbath on Dalal Street on Monday, benchmark indices Nifty 50 and the 30-scrip BSE Sensex ended lower, extending losses for the second...
-
India shares lower at close of trade; Nifty 50 down 2.18%
Investing.com – India equities were lower at the close on Monday, as losses in the Real Estate, Oil & Gas and Metals sectors propelled shares lower. At the close in NSE, the Nifty 50 fell...
-
Here’s Why Cipla is Rising in a Weak Mkt on Monday; Top Gainer on Nifty
By Malvika Gurung Investing.com -- In a weak market, with the two domestic benchmark equity indices in correction modes, one of the only two stocks trading in green on the 50-scrip Nifty50...
-
D-Street Bleeds on Monday as Indices Slump; 49 Stocks on Nifty50 Trade in Red
By Malvika Gurung Investing.com -- Following weak global market cues, the Indian equity benchmark indices Nifty 50 and BSE Sensex opened in red on Monday, declining further to 2.77% and...
-
A Closer Look at These Stocks on Dec 20: ITC, HDFC Bank & More
By Malvika Gurung Investing.com -- HDFC Bank Ltd (NS:HDBK): With a market share of over 10% and leading as the second largest bank in Tamil Nadu (NS:TNNP), the private lender’s SME loan...
-
Stocks to Watch: Airtel, ICICI, Hindalco, Shriram Properties, ONGC, Cipla
Consumer Durable stocks are also likely to be in focus on Monday after the company have hiked prices for the third time this year
-
Cipla receives final approval for Lanreotide Injection. Details here
Lanreotide Injection is used for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumours.
-
Cipla gets USFDA approval to market Lanreotide injection in US market
The company said it has received final approval for Lanreotide Injection from the US Food and Drug Administration (USFDA)
-
India shares higher at close of trade; Nifty 50 up 0.16%
Investing.com – India equities were higher at the close on Thursday, as gains in the IT, Technology and Consumer Durables sectors propelled shares higher. At the close in NSE, the Nifty 50...
-
Morning Watch Stocks for Dec 16: Tata Steel Ratings Upgrades, ICICI Bank & More
By Malvika Gurung Investing.com -- TVS Motor Company Ltd. (NS:TVSM): The two-wheeler and three-wheeler auto manufacturer announced on Wednesday to partner with BMW Motorrad for...
-
Top stocks in focus: Adani Ports, Vakrangee, Wipro, Cipla, Sun Pharma
Check out the stocks that will be in focus during trade today based on recent and latest news developments.
-
Drug major Cipla to acquire 33% stake in Clean Max Auriga Power
Post-acquisition, Clean Max Auriga Power LLP will become an associate of Cipla
-
Cipla acquires 33% stake in Clean Max Auriga Power
The company will invest up ₹6 crore for the 33% stake in the target firm
-
Cipla to acquire 33% stake in Clean Max Auriga Power
Clean Max Auriga Power LLP is a special purpose vehicle engaged in the business of production, supply, and distribution of solar, wind and other renewable energy.
-
Buy Cipla, target price Rs 1140: Emkay Global
Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 72715.79 Crore) operating in Pharmaceuticals sector.
-
Sun, Cipla, Gland Pharma should do well in FY23: Nithya Balasubramanian
"Sun Pharma shifted focus from generics to speciality, which seems to be doing well. Relatively they have a portfolio that is immune from price erosion."
-
India shares higher at close of trade; Nifty 50 up 1.56%
Investing.com – India equities were higher at the close on Tuesday, as gains in the Metals, Real Estate and Banking sectors propelled shares higher. At the close in NSE, the Nifty 50 rose...
-
Cipla Ltd eases for fifth straight session
Cipla Ltd is quoting at Rs 888.75, down 0.69% on the day as on 13:24 IST on the NSE. The stock jumped 16.02% in last one year as compared to a 28.35% rally in NIFTY and a 6.52% spurt in the...
-
5 Stocks to Watch Out for Amid the Omicron Outbreak
As the new variant of Covid-19 emerges, keep an eye on these stocks.
-
India shares higher at close of trade; Nifty 50 up 1.37%
Investing.com – India equities were higher at the close on Thursday, as gains in the Power, IT and Technology sectors propelled shares higher. At the close in NSE, the Nifty 50 added 1.37%,...
-
India shares higher at close of trade; Nifty 50 up 1.08%
Investing.com – India equities were higher at the close on Wednesday, as gains in the Metals, Banking and Auto sectors propelled shares higher. At the close in NSE, the Nifty 50 added...
-
Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December
Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
